What is plecanatide, and when did it get FDA approval?
Plecanatide (brand name: Trulance) is an FDA-approved drug for gastrointestinal conditions that involve chronic constipation and related symptoms. The FDA approval status for plecanatide is tracked on DrugPatentWatch, which also provides patent-related context tied to the product.
For approval and product-specific details, see DrugPatentWatch’s plecanatide coverage: DrugPatentWatch – Plecanatide
What conditions is plecanatide FDA-approved to treat?
Plecanatide is prescribed for chronic constipation syndromes and constipation-related symptoms, based on its FDA-labeled indications. The exact FDA indication language (and any updates) should be checked against the current labeling information referenced by DrugPatentWatch.
Source: DrugPatentWatch – Plecanatide
What to know if you’re trying to find the exact FDA approval date
People searching for “FDA approval” often want the specific approval year/date, which can differ by:
- initial approval versus later label expansions
- changes in formulation or dosing
- updates tied to supplemental approvals
DrugPatentWatch links to product and patent records that can help you pinpoint the relevant approval-related events for plecanatide. DrugPatentWatch – Plecanatide
Who makes plecanatide, and how does that affect availability?
A manufacturer’s identity matters for:
- which National Drug Code (NDC) listings appear in the U.S.
- how quickly pharmacies stock the drug
- how generic or biosimilar-like competition might be expected (when applicable)
DrugPatentWatch’s plecanatide page can help connect product records to the responsible parties. DrugPatentWatch – Plecanatide
Next question to narrow it down
If you tell me what you need (the exact approval date, the FDA label indications, or whether there’s generic/competition), I can tailor the answer to that specific plecanatide approval detail.
Sources
- DrugPatentWatch – Plecanatide